at every stage of the commercialization process and must transcend our commonly held reliance on regulation and oversight.
In sum, scholarship in entrepreneurship should broaden its focus to study the ethical choices of key social actors along the entrepreneurial pipeline and observe how entrepreneurs actually practice ethics. Research should look across disciplines to identify how key ethical principles and values are defined and used by different actors at each stage of the early commercial pathway. This research could result in an overarching ethics framework to guide academic entrepreneurs throughout the process of commercialization. In this way, entrepreneurial decisions become more ethical, leading to more efficient and beneficial regulatory outcomes. Such a framework has the potential to integrate ethics from idea to initial public offering and would provide a universal vocabulary for the ethical deliberation of entrepreneurial actors. Knowledge from this research could help redefine early life sciences ventures as socially responsible entities that are founded and run by individuals who think as deeply about morals as they do about money and markets.
The third way of umbilical cord blood banking quality control or be developed into a product. The banks collaborate with scientists in research institutes, hospitals and universities to provide the cells for transplantation, clinical trial and basic research. Breakthroughs in research and clinical trials ensure that the units are used efficiently. The cord blood donation program is supported by the income from the family banking program, which costs $2,500-3,500 to store one unit for 20 years, and from the release fee of the units for allogeneic transplants, which cost $7,000-30,000. This model has been adopted by Covina, California-based company StemCyte, and the national licensed cord blood banks in China.
A second hybrid model, and a variation on this theme, is the 'donatable family banking (Cún juān hù lì)' model. In this model, the cord blood units are family banked, but they can be searched by the wider public. Parents sign a commercial contract and pay a fee for the collection and storage of their child's cord blood sample. Units are tested, processed and typed for human leukocyte antigen (HLA). The cord blood units in the public bank are tested for the same disease markers as the donated units. HLA typing data are published on international registries and are available for searches for matches. If a unit is matched, the parents can decide whether they want to keep their cord blood unit, sell it or donate it to the patient in need of an allogeneic transplant. Donatable family banking overcomes the problem with family-banked samples, which cannot be used in searches or circulated, even though the likelihood that a family will ever use the unit is low. It is estimated that the inventory in private cord blood banks is double or triple that in the public banks 3 . This model opens a window for the public into the privately banked units, so that the units that have been collected and typed can be used more efficiently. In Asia, this model has been adopted by Bionet (BabyBanks) in Taiwan and Shanghai Cord Blood Bank in China.
In the above arrangements, ownership and accessibility of the units vary. In the public and private combination model, the company has ownership of the donated cord blood. The bank can provide the cells quickly for transplant because the cells are 'on the shelf ' . For example, StemCyte has facilitated more than 1,700 cord blood transplants globally, out of 29,000 donated cord blood units. In contrast, in the donatable family banking model, the cells belong to the customers. Banks using this model need to seek consent from the customer before a unit can be released.
Apart from clinical use of stem cells, these cord blood banks collaborate with The donated cord blood units in the public and private combination model and the units in the donatable family banking model can be found in the international registries for allogeneic transplantations. These units have been tested for markers of infectious diseases. Nevertheless, in the donatable family banking model, the units need not follow the high volume or total nucleated cells set for public banks, nor complete a six-month follow-up.
Finally, as with public banks, both models charge a release fee when a unit is used for transplantation. Greater financial input is required for an organization operating a public and private combination model because it does not charge collection and storage fees for the donated cord blood. The storage of the donated cord blood is very expensive. Even so, these banks attract income from their family banking and the release fee for the donated samples. Therefore, compared with the traditional public banks, the hybrid model lowers the risk of financial crisis. With the donatable family banking model, the financial burden is light as it charges a collection fee, a storage fee and usually a release fee as well. In addition, the price that parents pay to store the cord blood in the donatable family banking model is usually higher than that in the traditional family banking model because of extra services such as HLA typing and uploading data to international registries. Yet, this model is still welcomed by parents, who recognize that the likelihood of using the cord blood within their family is very low, and appreciate the opportunity to get a refund if the cord blood is matched and used by other patients.
In conclusion, whereas traditional public and private banking are two extremes of the spectrum, hybrid banking models provide a third way 4 . Some private companies are operating the public and private combination model that sustains the cord blood donation program with private funding. In addition, the donatable family banking model provides an opportunity for the family-banked cord blood units to be searched and used by the public. In these innovative hybrid models, private cord blood companies facilitate cell flow and research collaboration, rather than just driving profit. The industry and research collaboration can promote a winwin situation for stem call science. Finally, these two hybrid models could be useful for banks to collect cord blood and increase its use in allogeneic transplantation in countries without a government-funded cord blood donation program.
The morality of patents on preimplantation genetic diagnosis
To the Editor: Laura DeFrancesco's news story in the January issue on 23andMe's 'designer baby' patent brings up challenging moral questions related to patent law 1 . The patent describes a method for predicting the phenotypes of human offspring based on genetic characteristics of embryos 2 . The method could be employed by couples who are planning to use pre-implantation genetic diagnosis (PGD)-the genetic testing of embryos created by in vitro fertilization (IVF) before implantation-to avoid the birth of a child likely to develop a genetic disease 3, 4 .
However, PGD can be used not only to prevent diseases, but also to select for desired phenotypes, such as sex or eye color. As our knowledge of the genetic basis of complex phenotypes improves, it may be possible to use PGD to select for genetic propensities for intelligence, height, athletic or musical ability, or other traits 4 . Many people have objected to using PGD for purposes other than disease prevention because this would treat children as objects that can be manipulated or exploited, not as human beings with inherent dignity or moral worth 5, 6 . Others are concerned that using PGD to design children will deny them a right to an open future by constraining their choices related to careers, interests and life plans 7 , and some have argued that widespread use of PDG will exacerbate discrimination based on race, sex and disability 8 .
US patent law requires that inventions be novel, nonobvious and useful 9 . It does not require that inventions meet moral standards, although the courts have ruled that patents cannot be awarded on inventions that fulfill no lawful purpose 10 . Whereas many people have objected to human gene patents on moral grounds 11 , the US Supreme Court did not refer to moral arguments when it ruled that patents on isolated and purified DNA sequences are invalid. The court held that these patents are invalid because isolated and purified DNA sequences found in nature have not been changed enough to qualify as human inventions. Naturally occurring DNA sequences that have been modified by human beings in some way, such as complementary DNA (cDNA), can be patented 12 .
The situation in Europe is very different. Nations that belong to the European Union (EU) are bound to follow the European Directive on the Legal Protection of Biotechnological Inventions, adopted by the European Parliament in 1998, which prohibits patenting inventions that offend the ordre public (or public morality) 13 . Some examples of inventions that offend the public morality, according to the Directive, include processes for modifying the human germline or cloning
